Rhumbline Advisers Grows Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Rhumbline Advisers grew its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 23.7% during the second quarter, HoldingsChannel.com reports. The firm owned 121,595 shares of the company’s stock after purchasing an additional 23,266 shares during the period. Rhumbline Advisers’ holdings in Dyne Therapeutics were worth $4,291,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of DYN. Nisa Investment Advisors LLC grew its position in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in Dyne Therapeutics by 28.0% in the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after buying an additional 1,291 shares during the last quarter. EntryPoint Capital LLC bought a new position in shares of Dyne Therapeutics in the first quarter valued at $214,000. SG Americas Securities LLC acquired a new stake in shares of Dyne Therapeutics during the second quarter worth $217,000. Finally, Trexquant Investment LP acquired a new stake in Dyne Therapeutics during the 4th quarter worth about $304,000. Institutional investors own 96.68% of the company’s stock.

Wall Street Analyst Weigh In

DYN has been the topic of several research analyst reports. Stifel Nicolaus lifted their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. JPMorgan Chase & Co. boosted their target price on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research note on Tuesday, July 9th. Piper Sandler upped their target price on Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Chardan Capital lifted their price target on Dyne Therapeutics from $31.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, May 21st. Finally, Morgan Stanley increased their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.40.

Insider Transactions at Dyne Therapeutics

In other news, COO Susanna Gatti High sold 10,163 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $35.33, for a total value of $359,058.79. Following the sale, the chief operating officer now directly owns 148,792 shares in the company, valued at approximately $5,256,821.36. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO John Cox purchased 32,000 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the transaction, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Susanna Gatti High sold 10,163 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79. Following the completion of the transaction, the chief operating officer now owns 148,792 shares of the company’s stock, valued at approximately $5,256,821.36. The disclosure for this sale can be found here. 20.77% of the stock is owned by insiders.

Dyne Therapeutics Stock Up 1.0 %

NASDAQ:DYN opened at $34.40 on Tuesday. Dyne Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $47.45. The company’s 50 day moving average is $41.43 and its 200-day moving average is $33.43. The firm has a market cap of $3.01 billion, a price-to-earnings ratio of -8.66 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.02. Research analysts predict that Dyne Therapeutics, Inc. will post -2.96 EPS for the current fiscal year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.